Scholarlink

Background <p>Gastrointestinal nematodes such as hookworms (<i>Ancylostoma caninum</i>) and roundworms (<i>Toxocara canis</i>) commonly infect dogs and are zoonotic parasites capable of producing clinical disease in humans. This field study was conducted to confirm the clinical effectiveness and field safety of a novel, chewable tablet (Credelio Quattro<sup>™</sup>) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) as compared with a control product containing sarolaner, moxidectin, and pyrantel (as pamoate salt) for the treatment of naturally occurring gastrointestinal nematode infections in dogs.</p> Methods <p>In this multicenter field study, 158 dogs were enrolled with an evaluable safety population of 155 dogs and an evaluable effectiveness population of 109 dogs. Dogs were randomized in a 2:1 ratio to receive either the investigational veterinary product (IVP) Credelio Quattro containing lotilaner, moxidectin, praziquantel, and pyrantel or the control product (CP) containing sarolaner, moxidectin, and pyrantel. On Day 0, after confirmation of infection, enrolled dogs were randomized, dispensed, and administered IVP or CP. Enrolled dogs returned to the study site on Day 10 (± 2&#xa0;d) to quantify the concentration of nematode eggs post-treatment.</p> Results <p>Post-treatment fecal egg counts performed on Day 10 demonstrated a 99.9% reduction in <i>A. caninum</i> eggs per gram in both IVP-treated dogs and CP-treated dogs. In addition, a 98.7% and 96.6% reduction in <i>T. canis</i> fecal egg counts were observed in IVP- and CP-treated dogs, respectively. Adverse events were reported in both treatment groups. The most common adverse events reported in the IVP group included gastrointestinal signs, such as diarrhea and emesis, as well as lethargy.</p> Conclusions <p>This field study demonstrated that Credelio Quattro, a novel oral combination chewable tablet administered at the labeled dose ranges of 20–40&#xa0;mg/kg lotilaner, 0.02–0.04&#xa0;mg/kg moxidectin, 5–10&#xa0;mg/kg praziquantel, and 5–10&#xa0;mg/kg pyrantel (as pamoate salt), is safe and effective for the treatment and control of naturally occurring <i>A. caninum</i> and <i>T. canis</i> infections in dogs.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Field efficacy and safety evaluation of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel against gastrointestinal nematode infections in dogs in the USA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Samuel Charles,
  • Scott Wiseman,
  • Molly D. Savadelis,
  • Eric Nichols,
  • Lisa Young

摘要

Background

Gastrointestinal nematodes such as hookworms (Ancylostoma caninum) and roundworms (Toxocara canis) commonly infect dogs and are zoonotic parasites capable of producing clinical disease in humans. This field study was conducted to confirm the clinical effectiveness and field safety of a novel, chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) as compared with a control product containing sarolaner, moxidectin, and pyrantel (as pamoate salt) for the treatment of naturally occurring gastrointestinal nematode infections in dogs.

Methods

In this multicenter field study, 158 dogs were enrolled with an evaluable safety population of 155 dogs and an evaluable effectiveness population of 109 dogs. Dogs were randomized in a 2:1 ratio to receive either the investigational veterinary product (IVP) Credelio Quattro containing lotilaner, moxidectin, praziquantel, and pyrantel or the control product (CP) containing sarolaner, moxidectin, and pyrantel. On Day 0, after confirmation of infection, enrolled dogs were randomized, dispensed, and administered IVP or CP. Enrolled dogs returned to the study site on Day 10 (± 2 d) to quantify the concentration of nematode eggs post-treatment.

Results

Post-treatment fecal egg counts performed on Day 10 demonstrated a 99.9% reduction in A. caninum eggs per gram in both IVP-treated dogs and CP-treated dogs. In addition, a 98.7% and 96.6% reduction in T. canis fecal egg counts were observed in IVP- and CP-treated dogs, respectively. Adverse events were reported in both treatment groups. The most common adverse events reported in the IVP group included gastrointestinal signs, such as diarrhea and emesis, as well as lethargy.

Conclusions

This field study demonstrated that Credelio Quattro, a novel oral combination chewable tablet administered at the labeled dose ranges of 20–40 mg/kg lotilaner, 0.02–0.04 mg/kg moxidectin, 5–10 mg/kg praziquantel, and 5–10 mg/kg pyrantel (as pamoate salt), is safe and effective for the treatment and control of naturally occurring A. caninum and T. canis infections in dogs.

Graphical Abstract